Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIVN 401

Next Previous
Drug Profile

BIVN 401

Alternative Names: BIVN-401; Methylene blue - Oklahoma Medical Research; Methylthioninium chloride - Oklahoma Medical Research; Suvus; Virostat

Latest Information Update: 15 Dec 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oklahoma Medical Research Foundation
  • Developer Bioenvision
  • Class Antivirals; Phenothiazines; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis C
  • Discontinued Influenza virus infections; West Nile virus infections

Most Recent Events

  • 05 Dec 2008 No development reported - Preregistration for Hepatitis C in Egypt (PO)
  • 23 Oct 2007 Bioenvision has been acquired by Genzyme Corporation
  • 12 Sep 2007 Discontinued - Phase-II for Hepatitis C treatment in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top